TPN729MA

TPN729MA (TPN729 maleate) is a selective phosphodiesterase type 5 (PDE5) inhibitor with an IC50 value of 2.28 nM. TPN729MA affects erectile function and it can be used for the research of erectile dysfunction[1].

Signaling Pathways >> Metabolic Enzyme/Protease >> Phosphodiesterase (PDE)

Research Areas >> Neurological Disease

PDE5:2.28 nM (IC50)

PDE6:45.2 nM (IC50)

PDE1:566 nM (IC50)

PDE4:834 nM (IC50)

PDE11:6090 nM (IC50)

TPN729MA (1.25，2.5，5.0 mg/kg；1 次) 在所有时间点 5.0 mg/kg 剂量下增加海绵内压/血压比值 (ICP/BP)，在 2.5 mg/kg 剂量下 75，90，105 和 120 分钟时增加海绵内压/血压比[1]。 TPN729MA (5.0 μg/kg；静脉注射，1 次) 显著升高公比格犬的海绵内压和海绵内压/血压比[1]。 Animal Model: Male Sprague-Dawley rats with corpora cavernosa complete exposure[1] Dosage: 1.25, 2.5 and 5.0 mg/kg Administration: Intraduodenal (i.d.) injection; 1.25, 2.5 and 5.0 mg/kg, once Result: Dose-dependently increased the maximum intracavernous pressure (ICP) and ICP/blood pressure (BP).

[1]. Wang Z, et al. The selectivity and potency of the new PDE5 inhibitor TPN729MA. J Sex Med. 2013 Nov;10(11):2790-7.